RELAPSE MULTIPLE MYELOMA
Clinical trials for RELAPSE MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSE MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSE MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Vaccine-Drug combo targets Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests whether a personalized cancer vaccine (made by fusing a patient's own immune cells with their tumor cells) combined with the drug elranatamab is safe and works for people with multiple myeloma that has come back or stopped responding to prior treatmen…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated May 26, 2026 05:41 UTC
-
Double-Pronged cell therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study is testing a new treatment for people whose multiple myeloma has come back or stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, CD19 and BCMA, on myeloma cells to attack them. The stud…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 26, 2026 05:39 UTC
-
New hope for hard-to-treat myeloma with four-drug cocktail
Disease control Recruiting nowThis study is for people whose multiple myeloma has returned or stopped responding to standard treatments, including CAR T-cell therapy. Researchers want to see if combining four drugs—belantamab mafodotin, carfilzomib, pomalidomide, and dexamethasone—can shrink the cancer or slo…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 26, 2026 05:38 UTC
-
New drug cocktail aims to control relapsed blood cancer
Disease control Recruiting nowThis study tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if the combination is safe and helps control the cancer. About 62 adults who h…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Natalie Callander • Aim: Disease control
Last updated May 26, 2026 05:37 UTC
-
New vaccine boosts CAR-T power against Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy is safe and effective for people with multiple myeloma that has returned or not responded to treatment. About 25 adults will receive the vaccine along with CAR-…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: David Avigan • Aim: Disease control
Last updated May 26, 2026 05:35 UTC
-
Can a Follow-Up drug stop myeloma from returning after CAR t?
Disease control Recruiting nowThis study tests whether the drug elranatamab, given after CAR T-cell therapy (idecabtagene vicleucel), can lower the chance of multiple myeloma worsening. About 32 adults with relapsed or treatment-resistant myeloma will take part. The goal is to see if this combination helps mo…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 05:28 UTC
-
New combo therapy aims to tame Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive a drug called talquetamab to help control the cancer, followed by a one-time infusion of their own modified immune cells (ci…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New study aims to stop bitter side effect of myeloma drug
Symptom relief Recruiting nowThis study tests if certain preventive treatments can reduce or prevent taste changes caused by the drug talquetamab in people with multiple myeloma. About 210 participants will be randomly assigned to different preventive strategies. The goal is to improve quality of life by min…
Matched conditions: RELAPSE MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Symptom relief
Last updated May 20, 2026 11:57 UTC